Anúncio
Anúncio

ENLV

ENLV logo

Enlivex Therapeutics Ltd. Ordinary Shares

0.84
USD
Patrocinado
+0.02
+2.18%
08 de jan., 15:59 UTC -5
Encerrado
exchange

Pós-Mercado

0.84

0.00
-0.48%

Relatórios de Lucros ENLV

Rácio de surpresa positiva

ENLV separação 17 de 29 últimas estimativas.

59%

Próximo Relatório

Data do Próximo Relatório
30 de mar. de 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$0.11
Mudanças implicadas de Q3 25 (Revenue/ EPS)
--
/
+22.22%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
--
/
-52.17%

Enlivex Therapeutics Ltd. Ordinary Shares earnings per share and revenue

On 14 de nov. de 2025, ENLV reported earnings of -0.09 USD per share (EPS) for Q3 25, beating the estimate of -0.12 USD, resulting in a 26.47% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -1.63% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 3 analistas forecast an EPS of -0.11 USD, with revenue projected to reach -- USD, implying an aumentar of 22.22% EPS, and aumentar of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Citius Pharmaceuticals Inc. Common
Report Date
26 de dez. de 2025 Para Q4 25
Estimativa
-$0.49
Real
-
Surpresa
-
FAQ
For Q3 2025, Enlivex Therapeutics Ltd. Ordinary Shares reported EPS of -$0.09, beating estimates by 26.47%, and revenue of $0.00, 0% as expectations.
The stock price moved down -1.63%, changed from $0.99 before the earnings release to $0.98 the day after.
The next earning report is scheduled for 30 de mar. de 2026.
Based on 3 analistas, Enlivex Therapeutics Ltd. Ordinary Shares is expected to report EPS of -$0.11 and revenue of -- for Q4 2025.
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio